

## Original Article

# Prospective study of C reactive protein in chronic obstructive pulmonary disease (COPD) and its correlation with lung function

\*Rakesh Kumar Shahi<sup>1</sup>, Dr Mridul Bhusan<sup>2</sup>

<sup>1</sup>Associate Professor of Medicine, B.R.D Medical College, Gorakhpur, UP, India

<sup>2</sup>Assistant Professor, Government Medical College, Kannauj, UP, India

Corresponding author\*

### Abstract

**Background:** The link between increased C - reactive protein (CRP) and the prediction of cardiovascular risk has suggested that there might be an association between chronic obstructive pulmonary disease (COPD) and the increased incidence of cardiovascular disease (CVD) among other co-morbidities.

**Aim:** To study the relationship between the biomarker of systemic inflammation like C-reactive protein and disease severity, functional status and outcome in COPD patients over a period of 120 days after an acute exacerbation.

**Materials and Methods:** An observational cross-sectional study was done on 179 patients with COPD presenting in acute exacerbation (AECOPD) to Department of Medicine in Nehru Chikitsalay of B.R.D Medical College, Gorakhpur from January 2011 to June 2011. Forced expiratory volume (FEV1), BODE Index and COPD assessment test were studied. All patients underwent a detailed history and clinical examination at presentation and at follow up on day 15, 30 and 120.

**Results:** Male preponderance was observed (58.65%). Most of the patients were in the age group of 50 to 70 years (60.88%). The CRP was raised ( $\geq 3$  mg/l) in 75.97% patients out of that 79.61% attended day 120 follow up and the other, 24.02% patients did not have a raised CRP at the initial visit. Out of 27 patients who expired, 96.29% had raised CRP at initial presentation. A total 28 patients were lost during follow up.

**Conclusion:** Not all COPD patients had a raised CRP but in those who had a raised CRP, its levels were well correlated with lung function and functional status of the individual. CRP trends could be a predictor of death.

**Keys Words:** C - reactive protein, chronic obstructive pulmonary disease, Lung function

### Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable lung disorder characterized by progressive, poorly reversible airflow limitation often with systemic manifestations, in response to tobacco smoke and/or other harmful inhalational exposures.<sup>1</sup> Exacerbations and comorbidities contribute to the overall severity of disease and functional status in individual patients.<sup>1</sup>

COPD is frequently associated with comorbidities,<sup>1</sup> the most serious and prevalent being

atherosclerosis cardiovascular disease,<sup>2</sup> anorexia,<sup>2, 3</sup> lung cancer,<sup>1,4</sup> osteoporosis,<sup>3</sup> muscle weakness,<sup>1</sup> cachexia,<sup>3,1</sup> normocytic normochromic anemia, increased gastro esophageal reflux and clinical depression and anxiety. These comorbidities contribute to impaired functional capacity, worsening dyspnea, reduced health-related quality of life and increased mortality.

There are several biomarkers of systemic inflammation studied in COPD of which C-reactive protein and fibrinogen are very important. The link

between increased C - reactive protein and the prediction of cardiovascular risk has suggested that there might be an association between COPD and the increased incidence of CVD among other comorbidities.<sup>5,6</sup>

Statins are a group of drugs that has shown to have pleiotropic effects like anti-inflammatory and vasodilatory functions in addition to their lipid lowering effects.<sup>7</sup> Statin therapy has been shown to reduce CRP levels even in those with normal lipid levels. Though proven in coronary artery disease the role of statins in COPD is emerging.<sup>8</sup>

The present study was done to study the relationship between the biomarker of systemic inflammation like C-reactive protein and disease severity, functional status and outcome in COPD patients over a period of 120 days after an acute exacerbation.

#### **Material and methods**

An observational cross-sectional study was done on 179 patients with COPD presenting in acute exacerbation (AECOPD) to Department of Medicine in Nehru Chikitsalay of B.R.D Medical College, Gorakhpur from January 2011 to June 2011.

A written Informed consent and Institutional Medical Ethical Committee approval was taken before starting study.

All patients clinically diagnosed as AECOPD were included in the study. Patients with diabetes, hypertension and chronic kidney disease and who did not consent to be a part of the study were excluded from the study.

A record was maintained for height, weight, body mass index (BMI) and six minute walk distance for all patients. Forced expiratory volume (FEV1) was noted in all patients with the help of a spirometry done following the American thoracic guidelines for spirometry. Modified MRC Dyspnea Scale was used

to assess the severity of dyspnea in COPD patients as per the prescribed format by GOLD.

BODE Index for COPD which includes body mass index (B), degree of airflow obstruction (O), functional dyspnea (D) and exercise capacity (E) was also obtained from the patient's data. COPD Assessment Test was used to assess the impact of COPD on the functional status of the patient.

All the patients underwent a detail history and clinical examination at presentation and on follow up visits on days 15, 30 and 120.

#### **Results**

In present cross-sectional study out of 179 patients, 105 (58.65%) were male and 74 (41.34%) were female. Most of the patients were in the age group of 50 to 70 years (60.88%).

Comparison of mean CRP levels done by Mann Whitney test showed that mean CRP among males was  $29.07 \pm 42.07$  mg/l and that in females was  $39.05 \pm 63.05$  mg/l ( $p=0.93$ ).

The CRP was raised ( $\geq 3$  mg/l) in 136 (75.97%) patients out of that 82 (79.61%) attended day 120 follow up and the other, 43 (24.02%) patients did not have a raised CRP at the initial visit. Out of 27 patients who expired, 26 (96.29%) had raised CRP ( $\geq 3$ mg/l) at initial presentation. A total 28 patients were lost during follow up.

The mean CRP of the patients who had raised CRP at the acute exacerbation was  $34.55 \pm 47.18$ mg/l. At 120 day follow up visit, COPD patients still had a high CRP ( $\geq 3$ mg/l). Mean CRP was  $3.96 \pm 3.69$  mg/l.

Comparison of %predicted FEV1 (Day 15 follow up visit) levels in patients with CRP  $\geq 3$ mg/l and those with CRP  $< 3$ mg/l showed that patients with serum CRP levels  $\geq 3$  mg/l had significantly less FEV1 at

day 15 follow up visit, than those with CRP < 3 mg/l at presentation.

Mean 6 minute walk distance (at day 15 follow up visit) in patients with CRP ≥3mg/l was 317.92 ± 91.8 and those with CRP <3mg/l was 276.3±102.7 which means patients with serum CRP levels ≥ 3 mg/l had significantly less 6 minute walk distance at Day 15 follow up visit, than those with CRP<3 mg/l at presentation.

Median MMRC in patients (109) with CRP ≥3mg/l was 3 and patients (43) with CRP <3mg/l was 2 which means patients with serum CRP levels ≥ 3 mg/l had significantly worse MMRC dyspnea score than those with CRP < 3 mg/l at presentation.

CATest score in patients (109) with CRP ≥3mg/l was 24 and those with CRP <3mg/l CATest score was 21 which means patients with serum CRP levels ≥ 3 mg/l had significantly worse CAT test score dyspnea score than those with CRP < 3 mg/l at presentation.

**Table 1: Inter quartile analysis of CRP with respect to various lung function parameters**

Lung function parameter	CRP (mg/l)				P value
	I Quartile (0.2-2.6)	II Quartile (2.6-9)	III Quartile (9-26)	IV Quartile (26-212)	
	(n=39)	(n=37)	(n=37)	(n=37)	
6MWD(m)	92.4±97.6	263.8±104.5	241.7±99.2	202.4±109.3	0.001
MMRC	2	3	3	3	0.56
CAT	21	22	23	25.5	0.001
FEV1(% predicted)	44.5±17.2	2.16±15.1	38.9±14.2	34.6±13.6	0.001

CRP; C-reactive protein, 6MWD(m); six minute walk distance, MMRC; Modified Medical Research Council dyspnea scale, CAT; COPD Assessment Test, FEV1;forced expiratory volume in one second. With a higherCRP quartile, we observed a worse six minute walk distance, worse FEV1 and a worse COPD Assessment test score.

**Table 2:Correlation analysis between CRP with lung function parameters of survivors on corresponding visits**

	DAY1 (n=109)		DAY 15 (n=101)		DAY30 (n=86)		DAY 120 (n= 80)	
	r	P value	r	P value	r	P value	r	P value
6MWD	-	-	-0.24	0.003	-0.28	0.002	-0.33	0.0006
FEV1	-	-	-0.25	0.002	-0.24	0.01	-0.22	0.02
BODE	-	-	0.4	0.0001	0.23	0.01	0.35	0.0002
MMRC	0.41	0.0001	0.36	0.0001	0.31	0.0008	0.4	0.0001
CAT	0.42	0.0001	0.41	0.0001	0.37	0.0001	0.4	0.0001

CRP; C-reactive protein, 6MWD(m); six minute walk distance, MMRC; Modified Medical Research Council dyspnea scale, CAT; COPD Assessment Test, FEV1;forced expiratory volume in one second. CRP was significantly

correlated with Six minute walk distance, FEV1, MMRC and CATest score on each of the visits. (r= Pearson/Spearman correlation coefficient)

Correlation of change in CRP with change in Six minute walk distance, FEV1, MMRC and CATest score over 120 days showed that The change of CRP was significantly correlated with improvement in Six minute walk distance, FEV1, MMRC and CATest score over the study period of 120 days.

Out of those who had raised CRP at day1 and attended Day 120 followup visit, 44 patients had CRP  $\geq 3$  mg/l and 36 patients had CRP  $< 3$ mg/l at the Day 120 follow up visit.

Expired patients (27) had mean CRP (mg/l) of  $45.89 \pm 48.93$  and Survived (110) patients had CRP (mg/l) of  $25.4 \pm 3.4$  which means The COPD patients who expired during the post exacerbation period had a higher CRP at the acute exacerbation than those who survived. None of the patients who expired were on statin therapy.

Mean CRP at Day1 and Day 15 among patients who expired during the study was  $45.89 \pm 48.93$  and  $53.98 \pm 45.65$  respectively and in those who survived was  $25.32 \pm 42.66$  and  $7.98 \pm 10.35$  respectively.

**Table 3: Comparison of lung function parameters between statin and non statin group**

LFP	Day1			Day 30			Day 120		
	Statin (n=30)	Not statin (n=109)	P value	Statin (n=26)	Not statin (n=86)	P value	Statin (n=23)	Not statin (n=82)	P value
CRP	40.7 $\pm 8.7$	31.92 $\pm 4.2$	0.2	5.29 $\pm 0.9$	5.746 $\pm 0.8$	0.7	3.548 $\pm 0.6577$	3.973 $\pm 0.4718$	0.6
6mwd	254.2 $\pm 20.6$	234.5 $\pm 9.4$	0.4	300.6 $\pm 18.8$	304.7 $\pm 1.1$	0.8	312.7 $\pm 20.84$	317.9 $\pm 10.92$	0.8
FEV1	37.96 $\pm 2.7$	37.84 $\pm 1.3$	0.9	38.81 $\pm 2.7$	39.80 $\pm 1.5$	0.7	38.40 $\pm 2.941$	40.89 $\pm 1.508$	0.4
CAT	23	23	0.8	19	18	0.9	17	16	0.9
MMRC	3	3	0.7	2	2	0.6	2	2	0.57

CRP; C-reactive protein, 6MWD(m); six minute walk distance, MMRC; Modified Medical Research Council dyspnea scale, CAT; COPD Assessment Test, FEV1;forced expiratory volume in one second, LFP; Lung Function Parameters.

## Discussion

COPD is a life threatening disease with ever increasing incidence and prevalence. It has been called to be a “Silent epidemic” across the globe. COPD is frequently associated with comorbidities like cardiovascular disease, osteoporosis, anemia, depression, lung cancer among others which make their impact on health even more alarming.<sup>1,4</sup>

In a study done by Gupta R et al, the mean age of COPD patients was  $59.38 \pm 11.70$  years with a Male: Female ratio of 81:19. Our study has shown the similar results.<sup>9</sup>

We enrolled the patients as per the inclusion criteria and follow up was advised to them on days 15, 30 and 120 after the initial presentation. At the initial presentation, the mean CRP of all COPD patients was raised in COPD in acute exacerbation. This supports that there is evident systemic inflammation at the acute exacerbation of COPD. The rise in CRP at the exacerbation could be due to a response to infection as there was a group of 43 patients who had CRP  $<3\text{mg/l}$  at the acute exacerbation.

The decline in CRP levels on follow up may be a marker of recovery from the exacerbation of COPD among this subgroup of patients.

Among COPD patients who had CRP  $<3\text{ mg/l}$  at the initial presentation, there was no significant change in CRP on successive follow up visits thereafter. This suggests that COPD is a heterogenous disease with multiple phenotypes. Gupta R et al did a study in Rohtak and found that that CRP was raised at acute exacerbation of COPD and there was a significant decline in CRP on a follow up visit thereafter.<sup>9</sup>

We compared the pre exacerbation functional status among those with raised CRP ( $\geq 3\text{ mg/l}$ ) and those with CRP ( $< 3\text{ mg/l}$ ) at the acute exacerbation. We found that the group of patients with raised CRP had

a worse MMRC score and COPD Assessment Test score. They also had a worse FEV1 and six minute walk distance at the first follow up visits.

On interquartile analysis of the lung function parameters we found that the quartile with higher CRP had a statistically worse CAT test score and worse FEV1 and worse six minute walk distance at day 15 follow-up visit. (Table 1) This further supports that patients with more systemic inflammation had worse functional capacity and more severe airflow limitation. Table 2 showed correlation between CRP with lung function parameters of survivors on corresponding visits.

Torres D et al compared the clinical parameters of COPD patients with initial CRP values  $>3\text{mg/l}$  or  $\leq 3\text{mg/l}$  in a study, and they did not find any significant differences in FEV<sub>1</sub>, FVC, CI/CPT, GOLD stage, MMRC scale or BODE score between the two subgroups.<sup>10</sup> In our study, on the last follow up visit at 120 days after the initial presentation in the stable phase of the disease, COPD patients still had a raised CRP with the mean of  $3.96 \pm 3.67\text{ mg/l}$ , being higher than  $3\text{ mg/l}$  considered as the upper limit<sup>11</sup> denoting a parallel low grade systemic inflammation. This suggests that systemic inflammation is an inherent part of the disease both in the acute exacerbation as well as in the stable state. The ongoing systemic inflammation in COPD may be the link between COPD and the comorbidities often observed in COPD though further studies are required in this regard.

Halvani A et al did a study on 45 stable COPD patients and found that CRP was raised in COPD patients without potential confounders like ischemic heart disease and cigarette smoking.<sup>12</sup>

Although present study did not find any benefit of statin in all patients of COPD (Table 3), the role of

statins in acute exacerbation of COPD in patients with raised CRP will need to be studied in a larger prospective study.

Our study had some limitations. Firstly that a significant number of patients did not turn up for follow up at all the visit. Secondly, we used a turbidimetry method for measurement of CRP and not the ELISA method which is said to be the best method.<sup>13</sup>

### Conclusion

Present study showed that not all COPD patients had a raised CRP but in those who had a raised CRP, its levels correlated with lung function and functional status of the individual and CRP trends could be a predictor of death. In our study we found a definite correlation between CRP and lung function. COPD is the 'cause or effect' of systemic inflammation still needs to be established.

### References

1. Global Initiative for Chronic Obstructive Lung Disease guideline: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease; website. <http://www.goldcopd.com/>. Accessed June21 2011.
2. Ross R. Atherosclerosis: An inflammatory disease. *N Engl J Med* 1999;340:115-126.
3. Kotler DP, Cachexia. *Ann Inter Med* 2000; 133:622-34.
4. Gupta D, Agarwal R, Aggarwal AN, Maturu VN, Dhooria S, Prasad KT et al. For the COPD Guidelines Working Group, Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. *Lung India* 2011; 30 (3): 228-267.
5. Chung KF. Cytokines in chronic obstructive pulmonary disease. *Eur Respir J* 2001; 18: Suppl. 34, 50s-59s.
6. Dickens JA, Miller BE, Edwards ED, Silverman EK, Lomas DA, Singer RT. For the Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. *Respiratory Research* 2011, 12:146
7. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD *Eur Respir Rev* 2009; 18 (114): 222-232.
8. Ridker PM, Danielson E, Fonesca FA. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *New Engl J Med*. 2008; 359:21895-2207.
9. Gupta R, Kaur R, Singh V, Goyal V, Dahiya K, Gupta A, Kumawat M. Serial estimation of serum CRP levels in patients of COPD with acute exacerbation. *Global Journal of Medicine and Public Health* 2011; 1(6).
10. Torres DJP, Lanus CE, Aguilar LC, Fuentes MMD, Garcini MDA, Jaime AA, Celli BR, Casanova C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. *Eur Respir J* 2006; 27:902-907.
11. Morten Dahl, Jørgen Vestbo, Peter Lange, Stig E. Bojesen, Anne Tybjærg-Hansen, and Børge G. Nordestgaard. C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease; *Am J Respir Crit Care Med* 2007 Vol 175. pp 250-255
12. Halvani A, Nadooshan HH, Shoraki FK, Nasiriani K. Serum C-Reactive Protein Level in COPD Patients and Normal Population. *Tanaffos* 2007; 6(2): 51-55.
13. Campos JL, Arellano E, Calero C. Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays. *BMC Med Res Methodol* 2011; 12:40.